Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Overview of attention for article published in Radiation Oncology, November 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 46 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 5,473 followers.

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. https://t.co/D750VbyfNG H/T @NCBI #radonc #PubMed

29 Apr 2020

Reply Repost Favourite

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years | Radiation Oncology | Full Text https://t.co/8i1ig0UMCp

16 Nov 2019

Reply Repost Favourite

RT @radioncoluis: Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly…

14 Nov 2019

Reply Repost Favourite

14 Nov 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.